Pharmaceutical product for inducing magnified endogenous release of gut hormones, PYY and GLP-1, to reach a therapeutic effect for obesity and type 2 Diabetes Mellitus, prepared from an associative formula of macro and micronutrients in tablet forms or pills or mini-pills or micro-granules or micronized particles to be coated or microencapsulated with polymers or coating products or substances or microencapsulating products or substances, which, after ingestion, travels unchanged through the esophagus into the stomach, duodenum, and jejunum. The product was developed for travelling through the gastrointestinal tract, and, only after reaching the ileum, will suffer disintegration or breaking up of its coating, because of the specific pH encountered there, in the range of 6,0 to 7,0, then releasing its contents to cause an amplified stimulus on L cells, therein encountered in their highest concentration, to secrete the endogenous gut hormones PYY and GLP-1, which, through the bloodstream reach the arched nucleus in the hypothalamus (brain), causing intense inhibition of appetite, inducing the patient to reduce food intake and also stimulating the pancreatic Beta Cells (GLP-1) to secrete insulin while inhibiting pancreatic Alfa Cells in releasing glucagon, effects that results in better glycemic control in type 2 diabetic patients. Due to the product in question and the stimuli produced by it, beneficial effects of anti-obesity and control of Diabetes Mellitus 2 are obtained, presumably in similar ways as do bariatric-metabolic surgery, but without their inherent risks and potential early and late complications and, at the same time, facilitating the access of the massive numbers of individuals worldwide, suffering from obesity and/or type 2 diabetes mellitus to these benefits, because of the method simplicity.
